Analysis

May's top stories: Thermo Fisher Scientific buys Patheon for $7.2bn, AstraZeneca to sell rights for Seloken

May's top stories: Thermo Fisher Scientific buys Patheon for $7.2bn, AstraZeneca to sell rights for Seloken

Pooling resources for clinical trials

Pooling resources for clinical trials

Are cheap Canadian drugs a solution to US pricing issues?

Are cheap Canadian drugs a solution to US pricing issues?

BlueRock: Canada’s stem cell contender on the journey from petri dish to clinical trial

BlueRock: Canada’s stem cell contender on the journey from petri dish to clinical trial

Challenging the link between pharma innovation and US drug pricing

Challenging the link between pharma innovation and US drug pricing

Brain boosters: exploring the grey area of off-label ‘smart drugs’

Brain boosters: exploring the grey area of off-label ‘smart drugs’

Pharmaceutical packaging: where should drug companies focus their efforts?

Pharmaceutical packaging: where should drug companies focus their efforts?

Alzheimer’s drugs: will 2017 bring better news?

Alzheimer’s drugs: will 2017 bring better news?

Takeda turns its focus overseas

Takeda turns its focus overseas

BenevolentAI: using artificial intelligence to speed up drug discovery

BenevolentAI: using artificial intelligence to speed up drug discovery

Takeda and Ovid to Co-develop Drug for Rare Pediatric Epilepsies

Takeda and Ovid to Co-develop Drug for Rare Pediatric Epilepsies

How does the NHS weigh the costs of HIV preventing drugs?

How does the NHS weigh the costs of HIV preventing drugs?

India's drug price overhaul: a question of balance

India's drug price overhaul: a question of balance

Pay-for-delay: how far will companies go to protect market exclusivity?

Pay-for-delay: how far will companies go to protect market exclusivity?

Genomic array could unlock war against diseases in Africa

Genomic array could unlock war against diseases in Africa

Ibuprofen: could this ubiquitous drug be entering a whole new era?

Ibuprofen: could this ubiquitous drug be entering a whole new era?

Pfizer’s big antibiotic buyout: a sign of things to come?

Pfizer’s big antibiotic buyout: a sign of things to come?

Bernie vs. Big Pharma

Bernie vs. Big Pharma

October's top stories: GSK shingles vaccine, Pfizer’s Inflectra injection in US

October's top stories: GSK shingles vaccine, Pfizer’s Inflectra injection in US

Bringing together Oxford and Cambridge’s biopharma clusters

Bringing together Oxford and Cambridge’s biopharma clusters

September's top stories: US researchers developed Epilepsy drugs, GE's €150 million biopharmaceutical campus investment

September's top stories: US researchers developed Epilepsy drugs, GE's €150 million biopharmaceutical campus investment
cachename:Featurescachekey:rd-137342983_330948329_rd-1665407042_727740091_rd-488908060_1460672566_ap1460672566_727740091_-131204297